| 臺大學術典藏 |
2020-11-27T03:28:35Z |
From germ theory to germ therapy
|
CHIEH-CHANG CHEN; Chen Y.-N.; Liou J.-M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chien-Chuan Chen; Chen Y.-N.; CHIEH-CHANG CHEN; Fang Y.-J.; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:33Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chien-Chuan Chen; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Chen M.-J.; Fang Y.-J.; Wu M.-S.; CHIEH-CHANG CHEN; Chen Y.-N.; Yu C.-C.; Kuo C.-C.; Chiu M.-C.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen H.-H.; Bair M.-J.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:32Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
CHIEH-CHANG CHEN; Luo J.-C.; Fang Y.-J.; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; Shun C.-T.; Liu T.-Y.; Lee§ Y.-C.; Liou§ J.-M.; Wu§ M.-S.; and for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-02T02:04:33Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Lee Y.-C.; Wang W.-L.; Lee C.-T.; Tai C.-M.; MING-SHIANG WU; Bair M.-J.; Lin J.-T.; Sheu B.-S.; Wang H.-P.; Chang C.-C.; Yang T.-H.; Wu C.-Y.; Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Helicobacter Consortium; Taiwan Gastrointestinal Disease; Wang Y.-C. |
| 臺大學術典藏 |
2020-11-02T02:04:26Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Helicobacter Consortium; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU; the Taiwan Gastrointestinal Disease; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C. |
| 臺大學術典藏 |
2020-11-02T02:04:26Z |
Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection
|
Chen P.-Y.; MING-SHIANG WU; Chen C.-Y.; Bair M.-J.; Chou C.-K.; Lin J.-T.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-02T02:04:25Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium; Chang C.-C.; Luo J.-C.; Yang T.-H.; Lee J.-Y.; Hsu Y.-C.; Chen C.-C.; Tseng C.-H.; Chen M.-J.; Lee Y.-C.; Chang C.-Y.; Bair M.-J.; Chen C.-C.; Fang Y.-J.; Liou J.-M. |
| 臺大學術典藏 |
2020-11-02T02:04:20Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; MING-SHIANG WU; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-02T02:04:19Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Helicobacter Consortium; Taiwan Gastrointestinal Disease; MING-SHIANG WU; Bair M.-J.; Lee Y.-C.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G. |
| 臺大學術典藏 |
2020-11-02T02:04:13Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Helicobacter Consortium; Taiwan Gastrointestinal Disease; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; MING-SHIANG WU; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; MING-SHIANG WU; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S. |
| 臺大學術典藏 |
2020-11-02T02:04:09Z |
Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication
|
Helicobacter Consortium; Taiwan Gastrointestinal Disease; Wu C.-Y.; Liou J.-M.; MING-SHIANG WU; Lin J.-T.; Ho H.J.; Lee C.-C.; Hsu C.-C.; Yeo Y.H. |
| 臺大學術典藏 |
2020-11-02T02:04:03Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Helicobacter Consortium; Taiwan Gastrointestinal Disease; MING-SHIANG WU; El-Omar E.M.; Chuang E.Y.; Lu T.-P.; Lin J.-T.; Wu J.-Y.; Chen Y.-N.; Hsu W.-F.; Chen C.-Y.; Luo J.-C.; Yang T.-H.; Lee J.-Y.; Chen C.-C.; Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J. |
| 臺大學術典藏 |
2020 |
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan
|
Bair M.-J.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium; Chen H.-H.; Tsai M.-H.; Hsieh C.-L.; Chiu M.-C.; Hu W.-H.; Kuo C.-C.; Yu C.-C.; Chen Y.-N.; Chen C.-C.; MING-SHIANG WU; Fang Y.-J.; Chen M.-J. |
| 臺大學術典藏 |
2019 |
From germ theory to germ therapy
|
Chen C.-C.; Chen Y.-N.; Liou J.-M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Helicobacter Consortium; Taiwan Gastrointestinal Disease; Wu M.-S.; El-Omar E.M.; Liou J.-M.;Chen C.-C.;Chang C.-M.;Fang Y.-J.;Bair M.-J.;Chen P.-Y.;Chang C.-Y.;Hsu Y.-C.;Chen M.-J.;Chen C.-C.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Chen C.-Y.;Hsu W.-F.;Chen Y.-N.;Wu J.-Y.;Lin J.-T.;Tzu-Pin Lu;Chuang E.Y.;El-Omar E.M.;Wu M.-S.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; TZU-PIN LU; Chuang E.Y. |
| 臺大學術典藏 |
2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Helicobacter Consortium; Taiwan Gastrointestinal Disease; Wu M.-S.; El-Omar E.M.; Liou J.-M.;Chen C.-C.;Chang C.-M.;Fang Y.-J.;Bair M.-J.;Chen P.-Y.;Chang C.-Y.;Hsu Y.-C.;Chen M.-J.;Chen C.-C.;Lee J.-Y.;Yang T.-H.;Luo J.-C.;Chen C.-Y.;Hsu W.-F.;Chen Y.-N.;Wu J.-Y.;Lin J.-T.;Tzu-Pin Lu;Chuang E.Y.;El-Omar E.M.;Wu M.-S.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; TZU-PIN LU; Chuang E.Y. |
| 臺大學術典藏 |
2018 |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Helicobacter Consortium; for the Taiwan Gastrointestinal Disease; Liou J.-M.; Lin J.-T.; MING-SHIANG WU; Fang Y.-J.; Chen C.-C.; Chen Y.-N.; Chen C.-C.; Chen M.-J. |
